'They Stopped Treating and the Effect Persisted': What We Heard This Week

(MedPage Today) -- "Then they stopped treating, and the effect persisted."--Ronald Petersen, MD, PhD, of Mayo Clinic in Rochester, Minnesota, about outcomes in a phase II study of donanemab, an investigational agent for Alzheimer's disease...